IMF Videos Search Content For Care Partner (54) Patient (52) Healthcare Professional (39) Healthcare Provider (39) Series - Any - ASCO/EHA (17) ASH (10) Ask Dr. Durie (19) Black Swan Research Initiative (3) Community Workshops (3) Emerging Therapies (4) Facebook Live (2) Health Equity (3) IMWG (1) Living Well with Myeloma (3) Myeloma in a Minute (5) Myeloma Made Simple (3) Myeloma University (4) Patient & Family Webinar (1) Q&A (3) Recent News and Developments (1) Topics Clinical Trials (186) Financial Considerations (15) Frontline Therapy (84) Health Equity (34) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (72) Lifestyle (47) Mental & Emotional Health (29) Myeloma 101 (59) Myeloma in the News (8) Public Policy & Advocacy (17) Q&A's (43) Recorded Seminars & Workshops (15) Recorded Webinars (24) Relapse/Refractory Myeloma (138) Research Updates (194) Symptom Management (115) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (21) High-Risk Myeloma (26) High-risk Smoldering Myeloma (14) Late Relapse (4–6 Lines of Therapy) (17) MGUS (16) Newly Diagnosed (Pre-Treatment or First Treatment) (71) Smoldering Myeloma (25) Types of Therapy Immunomodulatory drugs (IMiDs) (39) Immunotherapies (CAR T; BiTE, etc.) (24) Monoclonal antibodies (29) Proteasome inhibitors (33) Stem cell transplant (41) Steroids (28) Supportive Care (18) Year Published 2026 (9) 2025 (16) 2024 (19) 2023 (13) 2022 (3) 2021 (4) 2019 (5) 2018 (2) 2017 (4) 2016 (5) 2015 (4) Trusted Voices Dr. Brian GM Durie (20) Dr. Joseph Mikhael (20) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (7) Dr. Shaji Kumar (2) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. María-Victoria Mateos (1) Dr. Saad Usmani (1) Dr. Sigurður Kristinsson (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance What is the role of ASCT in the frontline setting for African-American patients? May 9, 2024 Ask Dr. Durie Is the face of myeloma changing? February 20, 2024 Ask Dr. Durie Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients January 31, 2024 ASH Post American Society of Hematology (ASH) Summary January 25, 2024 ASH Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand) January 11, 2024 ASH Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma January 11, 2024 ASH Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for ASCT: Primary Results of the Perseus Trial January 8, 2024 ASH Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study January 8, 2024 ASH Ask Me Anything About Multiple Myeloma: Beth Faiman's Facebook Live Replay October 23, 2023 Facebook Live Myeloma University | Overview of Autologous Stem Cell Transplant for Treatment of Multiple Myeloma October 2, 2023 Myeloma University Myeloma Made Simple: Treatment for Patients Not Undergoing Transplant (Non-ASCT Transplant Eligible) September 28, 2023 Myeloma Made Simple Myeloma Made Simple: Monoclonal Antibodies Made Simple | Approved Therapies For Myeloma Treatment August 31, 2023 Myeloma Made Simple Load More
